Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
Primary Purpose
Ureteral Stent, Stent Related Symptoms
Status
Recruiting
Phase
Phase 3
Locations
Egypt
Study Type
Interventional
Intervention
Mirabegron 50 MG
Tamsulosin
Solifenacin Succinate 10 MG
Placebo oral tablet
Sponsored by

About this trial
This is an interventional treatment trial for Ureteral Stent focused on measuring Ureteral stone, Ureteral stent, Stent related symptoms, Quality of life
Eligibility Criteria
Inclusion Criteria:
- Adult patients (aged 19-80 years)
- Undergo unilateral uncomplicated retrograde rigid ureteroscopy (URS) or retrograde intrarenal surgery (RIRS) with planned ureteral stent insertion.
Exclusion Criteria:
- Patients with neurogenic bladder, OAB syndrome, and neurological and psychiatric diseases
- Residual ureteral or renal stones after the procedure
- Preoperative febrile UTI
- pregnancy or breastfeeding
- Bilateral ureteroscopic surgery
- Single kidney
- Chronic kidney disease
- Cardiovascular or cerebrovascular disease
- Hepatic dysfunction
- History of pelvic surgery or irradiation
- History of bladder or prostate surgery
- Other acute medical conditions as acute gastroenteritis, osetoarthritis that might influence the patient QoL
- Preoperative indwelling of ureteral stent for relief of stone-related pain or sepsis
Sites / Locations
- Urology and Nephrology CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Placebo Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
Placebo arm
Mirabegron arm
Tamsulosin arm
Solifenacin arm
Arm Description
Patients in this arm will receive a placebo formula
Patients in this arm will receive Mirabegrone 50 mg once daily
Patients in this arm will receive tamsulosin o.4 mg once daily
Patients in this arm will receive solifenacin 10 mg once daily
Outcomes
Primary Outcome Measures
Improvement in stent related symptoms using ureteral stent symptoms questionnaire (USSQ)
The effect of the assigned treatment on improvement of stent related symptoms will be assessed at the time of stent removal using ureteral stent symptoms questionnaire (USSQ)
Secondary Outcome Measures
Adverse event of medications
Side effects of the assigned treatment will be monitored
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04325880
Brief Title
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
Official Title
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2021 (Anticipated)
Primary Completion Date
June 1, 2022 (Anticipated)
Study Completion Date
July 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mansoura University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
The primary objective of this prospective, single-centre randomized controlled trial is to assess the efficacy of three different drugs in treatment of ureteral stents related symptoms (Beta 3 adrenergic receptor agonist; Mirabegron 50mg) vs. (Alpha 1 adrenergic receptor antagonist; Tamsulosin 0.4mg) vs. (Anticholinergic; Solifenacin 10 mg) using validated symptoms questionnaires.
In addition, adverse events of the utilized medications will be monitored during study period as a secondary objective.
Detailed Description
Indwelling ureteral stents are specialized catheters designed to alleviate obstruction by maintaining the patency of the ureteral lumen and to splint the ureter by acting as a scaffold to promote organized tissue healing. (1)
Common issues associated with contemporary ureteral stents include stent-related pain, hematuria, dysuria, urgency, infection, and encrustation (2). Majority of patients (80%) reported one or more urinary symptoms with over 80% of patients experience stent-related pain that affects daily activities, 58% report reduced work capacity, and 32%report sexual dysfunction (2). In addition, as many as 32% of patients had ureteral stents removed sooner than anticipated because of these complications (3).
Considering this high prevalence of ureteral stent related symptoms (uSRS) among patients and its potential impact on quality of life (QoL), adequate management of these bothering symptoms was the point of research over the last decades (4).
The exact mechanism involved in uSRS is not yet known; however, many authors report that such symptoms are associated with ureteral spasms, urinary reflux attributable to ureteral stent, or trigonal irritation (5).
Different novel types of stents have been developed and evaluated to reduce uSRS; however, there is still controversy regarding their clinical application (6). Conversely, pharmacological therapy, including anticholinergics and alpha-blockers, remains the most effective option to manage uSRS (7).
The role of a-blockers in reducing uSRS involves reduction of bladder outlet resistance to alleviate flank pain in male patients with preexisting bladder outlet obstruction (BOO). It has been proposed that relaxing the distal ureter and irritation of the trigone decreases bladder outlet resistance and voiding pressure, thereby potentially decreasing the incidence of renal reflux and subsequent flank pain (8) . Otherwise, anticholinergic agents may have an effect on involuntary contractions of the bladder induced by the distal end of ureteral stents with subsequent relief of uSRS (9).
The above-mentioned drugs, however, are not easy to apply to some patients with co-morbidities because of the potential side effects. The most common medication-related complications of a-blockers are dizziness and orthostatic hypotension. Depending on the type of medication, medication-related adverse events are reported at a rate of 5% to 20% (10). In addition, anticholinergic agents have various adverse effects that decrease treatment compliance, such as dry mouth, constipation, blurred vision and dyspepsia (11).
Beta-3 agonist mirabegron is believed to be responsible for the relaxation of the detrusor smooth muscle during the storage phase (12). It helps relax the detrusor smooth muscle, and results in increased bladder capacity without any changes in micturition pressure, post-void residual urine volume, or voiding contractions.
Considering the function of mirabegron as a therapeutic agent for overactive bladder (OAB), mirabegron is assumed to be effective for relieving voiding symptoms attributable to uSRS (13).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ureteral Stent, Stent Related Symptoms
Keywords
Ureteral stone, Ureteral stent, Stent related symptoms, Quality of life
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
240 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Placebo arm
Arm Type
Placebo Comparator
Arm Description
Patients in this arm will receive a placebo formula
Arm Title
Mirabegron arm
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive Mirabegrone 50 mg once daily
Arm Title
Tamsulosin arm
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive tamsulosin o.4 mg once daily
Arm Title
Solifenacin arm
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive solifenacin 10 mg once daily
Intervention Type
Drug
Intervention Name(s)
Mirabegron 50 MG
Intervention Description
Patients in this arm will receive Mirabegrone 50 MG once daily
Intervention Type
Drug
Intervention Name(s)
Tamsulosin
Intervention Description
Patients in this arm will receive Tamsulosin o.4 MG once daily
Intervention Type
Drug
Intervention Name(s)
Solifenacin Succinate 10 MG
Intervention Description
Patients in this arm will receive Solifenacin Succinate 10 MG once daily
Intervention Type
Drug
Intervention Name(s)
Placebo oral tablet
Intervention Description
Patients in this arm will receive placebo oral tablet once daily
Primary Outcome Measure Information:
Title
Improvement in stent related symptoms using ureteral stent symptoms questionnaire (USSQ)
Description
The effect of the assigned treatment on improvement of stent related symptoms will be assessed at the time of stent removal using ureteral stent symptoms questionnaire (USSQ)
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Adverse event of medications
Description
Side effects of the assigned treatment will be monitored
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients (aged 19-80 years)
Undergo unilateral uncomplicated retrograde rigid ureteroscopy (URS) or retrograde intrarenal surgery (RIRS) with planned ureteral stent insertion.
Exclusion Criteria:
Patients with neurogenic bladder, OAB syndrome, and neurological and psychiatric diseases
Residual ureteral or renal stones after the procedure
Preoperative febrile UTI
pregnancy or breastfeeding
Bilateral ureteroscopic surgery
Single kidney
Chronic kidney disease
Cardiovascular or cerebrovascular disease
Hepatic dysfunction
History of pelvic surgery or irradiation
History of bladder or prostate surgery
Other acute medical conditions as acute gastroenteritis, osetoarthritis that might influence the patient QoL
Preoperative indwelling of ureteral stent for relief of stone-related pain or sepsis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amr A Elsawy
Phone
0502202222
Email
amrelsawy.unc@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ahmed S Elhefnawy
Phone
0502202222
Email
a_s_elhefnawy@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amr A Elsawy
Organizational Affiliation
Mansoura University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Urology and Nephrology Center
City
Mansoura
State/Province
DK
ZIP/Postal Code
35516
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amr A Elsawy
Phone
0502202222
Email
amrelsawy.unc@hotmail.com
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
We'll reach out to this number within 24 hrs